Castle Biosciences (CSTL) said Monday its DecisionDx-Melanoma clinical test for patients with cutaneous melanoma reached 200,000 orders.
The 31-gene expression profile test offers personalized results detailing a patient's predicted risk of recurrence or metastasis, the company said.
Shares were down 2.8% in recent trading.
Price: 20.05, Change: -0.58, Percent Change: -2.84
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.